{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:14:57Z","timestamp":1788221697548,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018152","name":"Institute for Health Economics and Policy","doi-asserted-by":"publisher","award":["Research Grant for Young Researchers in 2022"],"award-info":[{"award-number":["Research Grant for Young Researchers in 2022"]}],"id":[{"id":"10.13039\/100018152","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Science and Technology Agency (JST), Core Research for Evolutional Science and Technology","award":["JPMJCR21M1"],"award-info":[{"award-number":["JPMJCR21M1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multidisciplinary cancer treatments have advanced significantly, especially with molecular targeted therapies improving prognosis. Although these are expensive, their cost impact remains unverified. This study aimed to investigate the overall utilization of healthcare resources and identify the cost drivers of cancer treatment in Japan. In this retrospective cohort study, patients diagnosed with malignancies between April 2011 and March 2022 were classified by cancer type, and monthly insurance claims and applicable medications were analyzed. Breast cancer was the most common, followed by stomach and colon cancers. Cost analysis by cancer type revealed that lung cancer was the most expensive overall, whereas multiple myeloma was the most expensive per person-month. When antineoplastic drug costs were aggregated by mechanism, a rapid increase was observed in the immune checkpoint inhibitor category. Since the advent of immune checkpoint inhibitors, the number of insurance claims for antineoplastic drugs in Japan has increased. Japan\u2019s public healthcare system has seen an increase in the cost of cancer treatment at a rate exceeding national economic growth. These findings highlight the need for policies that address the cost-effectiveness and sustainability of cancer care to ensure continued access to high-quality treatment within publicly funded systems in Japan and globally.<\/jats:p>","DOI":"10.1038\/s41598-026-55013-x","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:16:20Z","timestamp":1781536580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A nationwide survey of medical resource usage for cancer treatment using Japanese health claims data from 2011 to 2022"],"prefix":"10.1038","volume":"16","author":[{"given":"Keita","family":"Fukuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"55013_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"55013_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.15537\/1658-3175.8333","volume":"45","author":"Global cancer burden growing","year":"2024","unstructured":"Global cancer burden growing. amidst mounting need for services. Saudi Med J. 45, 326\u2013327 (2024).","journal-title":"Saudi Med J."},{"key":"55013_CR3","unstructured":"National comprehensive cancer network. Non-Small Cell Lung Cancer - Guidelines Detail, https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450 (2025)."},{"key":"55013_CR4","unstructured":"National comprehensive cancer network. Hepatocellular Carcinoma - Guidelines Detail, https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1514 (2025)."},{"key":"55013_CR5","unstructured":"National comprehensive cancer network. Kidney Cancer - Guidelines Detail, https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1440 (2025)."},{"key":"55013_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","volume":"87","author":"M Siddiqui","year":"2012","unstructured":"Siddiqui, M. & Rajkumar, S. V. The high cost of cancer drugs and what we can do about it.. Mayo Clin. Proc. 87, 935\u2013943 (2012).","journal-title":"Mayo Clin. Proc."},{"key":"55013_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 9, 465\u2013472 (2023).","journal-title":"JAMA Oncol."},{"key":"55013_CR8","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/S0140-6736(19)32407-9","volume":"394","author":"X Shen","year":"2019","unstructured":"Shen, X. et al. Effect of insurance-reimbursed inpatient cancer care in Anhui Province: a retrospective study. Lancet 394, S71 (2019).","journal-title":"Lancet"},{"key":"55013_CR9","unstructured":"National Cancer Center Japan. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan., https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html (2025)."},{"key":"55013_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.37737\/ace.24011","volume":"6","author":"H Yasunaga","year":"2024","unstructured":"Yasunaga, H. Updated information on NDB. Ann. Clin. Epidemiol. 6, 73\u201376 (2024).","journal-title":"Ann. Clin. Epidemiol."},{"key":"55013_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.37737\/ace.2.1_13","volume":"2","author":"N Hirose","year":"2020","unstructured":"Hirose, N., Ishimaru, M., Morita, K. & Yasunaga, H. A review of studies using the Japanese national database of health insurance claims and specific health checkups. Ann. Clin. Epidemiol. 2, 13\u201326 (2020).","journal-title":"Ann. Clin. Epidemiol."},{"key":"55013_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10147-021-02079-4","volume":"27","author":"N Hoshino","year":"2022","unstructured":"Hoshino, N. et al. Relationship between diverting stoma and adjuvant chemotherapy in patients with rectal cancer: a nationwide study using the national database of health insurance claims and specific health checkups of Japan. Int. J. Clin. Oncol. 27, 545\u2013552 (2022).","journal-title":"Int. J. Clin. Oncol."},{"key":"55013_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99516-1","volume":"11","author":"S Ohtera","year":"2021","unstructured":"Ohtera, S. et al. A nationwide survey on participation in cardiac rehabilitation among patients with coronary heart disease using health claims data in Japan. Sci. Rep. 11, 20096 (2021).","journal-title":"Sci. Rep."},{"key":"55013_CR14","volume-title":"Cancer Incidence in Five Continents, Vol. XII (IARC CancerBase No. 19)","author":"F Bray","year":"2023","unstructured":"Bray, F. et al. Cancer Incidence in Five Continents, Vol. XII (IARC CancerBase No. 19) (International Agency for Research on Cancer, 2023). Available from: https:\/\/ci5.iarc.who.int accessed 26 May 2024."},{"key":"55013_CR15","unstructured":"Health insurance claims review and reimbursement services. Electronic Point Table Basic Master, Social Insurance Medical Fee Payment Fund, https:\/\/www.ssk.or.jp\/seikyushiharai\/tensuhyo\/index.html (Japanese) (2023)."},{"key":"55013_CR16","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"55013_CR17","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"55013_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"55013_CR19","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","volume":"11","author":"HR Abrams","year":"2021","unstructured":"Abrams, H. R. et al. Financial toxicity in cancer care: Origins, impact, and solutions. Transl. Behav. Med. 11, 2043\u20132054 (2021).","journal-title":"Transl. Behav. Med."},{"key":"55013_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","volume":"389","author":"O Ginsburg","year":"2017","unstructured":"Ginsburg, O. et al. The global burden of women\u2019s cancers: A grand challenge in global health. Lancet 389, 847\u2013860 (2017).","journal-title":"Lancet"},{"key":"55013_CR21","unstructured":"Ministry of health labour and welfare of Japan. Regarding the FY2024 medical fee revision explanatory materials, etc, https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000196352_00012.html (2024)."},{"key":"55013_CR22","unstructured":"Cabinet office government of Japan. SNA (National Accounts of Japan), https:\/\/www.esri.cao.go.jp\/jp\/sna\/menu.html (2025)."},{"key":"55013_CR23","unstructured":"Ministry of health labour and welfare of Japan. Agenda for the 64th meeting of the Cost-Effectiveness Evaluation Special Committee of the Central Social Insurance Medical Council, https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000182080_00015.html (Japanese) (2023)."},{"key":"55013_CR24","unstructured":"Cabinet office government of Japan. About the Next Generation Medical Infrastructure Act, https:\/\/www8.cao.go.jp\/iryou\/gaiyou\/gaiyou.html (Japanese) (2025)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55013-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55013-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55013-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:35:39Z","timestamp":1788219339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55013-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55013"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55013-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.M. reports payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Daiichi Sankyo Company. H.U. reports contracts from Mitsubishi Tanabe Pharma, Sumitomo Pharma, Takeda Pharmaceutical, and Ono Pharmaceutical CO., LTD. S.M. reports payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Novartis Pharma K.K., Taiho Pharmaceutical CO., LTD., and Ono Pharmaceutical CO., LTD. The other authors declare no conflicts of interest associated with this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27362"}}